Betalains for Health & Longevity - Quick Reference Sheet

Betalains for Health & Longevity

Created on 09/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Betalains are the red and yellow pigments of beetroot, prickly pear, chard and red dragon fruit. Human evidence is modest and specific: small, consistent endurance and recovery gains in trained adults, and better blood-vessel and cholesterol markers in people with existing heart disease. Everything broader rests on cells, worms and rodents. Harmless red urine is the main documented effect. (Full Review)

Protocol

Standard concentrate protocol
100 mg daily, then 50 mg pre-session
Betalain-rich beetroot concentrate as two 50 mg capsules, roughly 25 mg betalains, for six days, then 50 mg taken 120–150 minutes before the target session
Vascular protocol
25 mg betalains daily for 28 days
One daily capsule; the published dragon-fruit trial used 33 mg daily for 14 days
Whole-food alternative
85 g beetroot ≈ 100 mg betalains
Several times the concentrate dose, but adds sugar, nitrate and oxalate to the exposure
Time to effect
Endurance Exercise Performance and Recovery
Six days of loading
Performance trials then dosed 120–150 minutes before exercise
Endothelial Function and Arterial Stiffness
2–4 hours
Artery widening appears after a single dose and persists at 14 days
Atherogenic Lipids and Homocysteine
2 weeks
Marker changes seen in men with established coronary artery disease

Benefits

Contraindications
  • Organic nitrates and PDE5 inhibitors with nitrate-containing beetroot juice
  • Recurrent calcium oxalate stone formers using whole-food sources (24-hour urinary oxalate above 40 mg)
  • Documented beet or Amaranthaceae allergy
  • Symptomatic hypotension (seated systolic below 100 mmHg) or three or more antihypertensive agents
  • Chronic kidney disease stage 4–5 using oxalate-rich whole-food sources
  • Pregnancy and lactation at concentrate doses
  • Metal-accumulating disease (hemochromatosis, Wilson disease, porphyria cutanea tarda) at high whole-beet intakes
Key Interactions
  • Antihypertensive drugs (lisinopril, ramipril, losartan, valsartan, amlodipine)
  • Glucose-lowering drugs (metformin, glipizide, glibenclamide, empagliflozin)
  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, warfarin, apixaban)
  • Proton pump inhibitors and H2 blockers (omeprazole, famotidine)
  • Pressure-lowering supplements (L-citrulline, L-arginine, hibiscus, magnesium, potassium)
  • Calcium taken with oxalate-rich beet greens
  • Chronic high-dose antioxidant supplementation around training (vitamin C above 1 g, vitamin E above 400 IU)

Risk & Side Effects

  • High: Beeturia and red-pigmented urine or stool
  • Low: Additive blood-pressure lowering; oxalate burden from whole-food sources; nitrate co-exposure from beetroot vehicles; allergic reactions
  • Speculative: Interference with drug-metabolizing enzymes; unknown long-term safety at concentrated doses; hepatic metal accumulation from whole-beet loading

Monitoring

Marker Target Why
Low-density lipoprotein cholesterol (LDL-C) <100 mg/dL; <70 mg/dL with vascular disease Changed meaningfully in the only lipid trial
Non-high-density lipoprotein cholesterol <130 mg/dL; <100 mg/dL with vascular disease Captures every artery-damaging particle
Homocysteine 5–8 µmol/L Most responsive marker in the coronary trial
Fasting glucose 75–90 mg/dL Tests the glycemic claim directly
Glycated hemoglobin (HbA1c) 4.8–5.3% Integrates three months of glucose exposure
Seated blood pressure 110–120 / 70–78 mmHg Detects both the benefit and the additive hypotension risk
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L Tests the anti-inflammatory claim
Urinalysis with microscopy if positive No blood, no protein Establishes that red urine is pigment, not bleeding
Serum ferritin and transferrin saturation Ferritin 50–150 ng/mL; saturation 25–35% Beeturia frequency tracks iron status
24-hour urinary oxalate <25 mg/24 h Only for heavy beet-green or chard intake
Estimated glomerular filtration rate (eGFR) with creatinine eGFR >90 mL/min/1.73 m² Context for tolerating an oxalate load

Cadence: Blood pressure at 2 and 4 weeks; the lipid, homocysteine and glucose panel at 8–12 weeks; then every 6–12 months while intake continues. A 24-hour urinary oxalate measurement is added at 12 weeks with large amounts of beet greens or chard.

Qualitative Assessment

  • Perceived exertion during steady-state work: a partial rather than a consistent signal
  • Next-day muscle soreness and fatigue: a weak signal
  • Urine and stool color: expected, harmless, and the earliest visible sign that pigment is passing through
  • Lightheadedness on standing: the practical signal of additive blood-pressure lowering in anyone on cardiovascular medication
  • Energy and cognitive clarity: untested for betalains specifically, useful only as a personal trend against a documented baseline